Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Pulmonary Embolism Market from 2024 to 2025?

In recent years, the market size for pulmonary embolism has seen substantial expansion. The predicted growth is from $2.03 billion in 2024 to $2.27 billion in 2025, achieving a compound annual growth rate (CAGR) of 11.9%. The notable increase in the historic period can be linked to anticoagulant therapies, various research and clinical trials, heightened awareness of pulmonary embolism, and VTE prophylaxis.

What Is the Projected Market Size of the Pulmonary Embolism Market?

In the upcoming years, the market size for pulmonary embolism is projected to experience a swift expansion. The market value is anticipated to reach $3.63 billion in 2029, growing at a Compound Annual Growth Rate (CAGR) of 12.5%. The predicted growth in this period can be credited to a focus on targeted therapies, the augmenting role of telemedicine, and remote monitoring, with initiatives towards health equity and worldwide health contributing to this expansion. Some significant trends to watch during this forecast period include the implementation of artificial intelligence in diagnosis, the development of unique anticoagulants, the formation of pulmonary embolism response teams, and an increased emphasis on patient-oriented care.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13026&type=smp

Who are the Major Competitors in the Pulmonary Embolism Market Outlook?

Major companies operating in the pulmonary embolism market are Pfizer Inc., Johnson and Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co.Inc., Novartis AG, Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, GSK PLC, Abbott Laboratories, AstraZeneca PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Mitsubishi Tanabe Pharma Corporation, Genentech Inc., Hikma Pharmaceuticals PLC, Aspen Pharmacare Holdings Limited, Nippon Shinyaku Co. Ltd., Penumbra Inc., Fresenius Kabi AG, Inari Medical Inc., AngioDynamics Inc., Otsuka Pharmaceutical Co. Ltd.

What Is Fueling Growth in the Pulmonary Embolism Market?

The growing occurrence of blood clots is predicted to fuel the expansion of the pulmonary embolism market. A blood clot or thrombus is a gelatinous or semisolid clot that forms inside a blood vessel. Such clots can precipitate a pulmonary embolism by hindering the blood flow to the lungs. The clot usually causes a blockage in the deep veins of the legs, consequently heightening the probability of a pulmonary embolism. For example, in April 2022, Gavi, the Vaccine Alliance, an international union established to enhance access to new and underused vaccines for children, published an article reporting a 33-fold increase in the likelihood of life-threatening lung clotting, and a 5-fold upsurge in the risk of deep vein thrombosis over 30 days post-COVID-19 exposure. Hence, the rising occurrence of blood clots is fueling the pulmonary embolism market’s growth. The escalation in cancer occurrences is anticipated to boost the growth of the pulmonary embolism market further. Cancer is a cluster of diseases marked by the unregulated and abnormal cell growth in our bodies. The rise in cancer incidences elevates the chances of clotting disorders like pulmonary embolism in cancer patients, thereby creating a higher demand for diagnostic tests and treatments, including specialized medications. For example, in January 2024, the American Cancer Society, a nonprofit US-based cancer advocacy group, reported an increase of 2.19% in cancer cases from 1,958,310 in 2023 to 2,001,140. Consequently, the rising prevalence of cancer is pushing the pulmonary embolism market higher.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13026&type=smp

Which Pulmonary Embolism Market Segments Are Growing the Fastest?

The pulmonary embolism market covered in this report is segmented –

1) By Treatment: Medications, Mechanical Devices, Other Treatments

2) By Diagnosis: Chest X-Ray, Electrocardiogram (ECG), Magnetic Resonance Imaging (MRI), Computed Tomography Scan, Pulmonary Angiography, Venography, Venous Ultrasound, D-Dimer Test, Other Diagnosis

3) By Symptoms: Shortness Of Breath, Chest Pain, Cough, Irregular Heartbeat, Dizziness, Fever, Cyanosis, Other Symptoms

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Medications: Anticoagulants, Thrombolytics

2) By Mechanical Devices: Inferior Vena Cava (IVC) Filters, Catheter-Assisted Thrombectomy

3) By Other Treatments: Surgical Embolectomy, Supportive Care

Which Industry Trends Are Shaping the Future of the Pulmonary Embolism Market?

Leading businesses in the pulmonary embolism market are concentrating their efforts on creating unique products like the Triever16 Curve catheter and the RevCore thrombectomy catheter in the pursuit of a dominant position. For example, Inari Medical Inc., an American medical technology firm, inaugurated the Triever16 Curve catheter and the RevCore thrombectomy catheter in June 2023. The Triever16 Curve catheter, a groundbreaking product, is engineered for peripheral thrombectomy and pulmonary embolism operations, boasting superior trackability, a pre-shaped curve for dedicated aspiration, and a unique design that facilitates easy entry to larger and more effective 20F or 24F catheters. Consequently, the RevCore thrombectomy catheter is constructed to cure venous in-stent thrombosis, functioning as a mechanical thrombectomy device that employs a nitinol basket to trap and dispose of blood clots. In addition, these catheters enhance the safety and efficiency of pulmonary embolism procedures.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pulmonary-embolism-global-market-report

Which Countries Are Leading the Pulmonary Embolism Market?

North America was the largest region in the pulmonary embolism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pulmonary embolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13026

This Report Delivers Insight On:

1. How big is the pulmonary embolism market, and how is it changing globally?

2. Who are the major companies in the pulmonary embolism market, and how are they performing?

3. What are the key opportunities and risks in the pulmonary embolism market right now?

4. Which products or customer segments are growing the most in the pulmonary embolism market?

5. What factors are helping or slowing down the growth of the pulmonary embolism market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model